The Oral GLP-1 Race Novo Nordisk's oral semaglutide (Rybelsus) demonstrated that GLP-1 receptor agonists can be delivered orally overcoming the injection barrier that has limited adoption, particularly in developing markets and among needle-averse patients
The FDA-approved finished products containing semaglutide and tirzepatide are administered via injection
We all experience stress at some point during our busy lives, but if we are unable to manage this stress, it can lead to much greater issues down the road, including chronic diseases or cancer
Article 8 mins Using Climate Data to Protect Employee Health Employers are increasingly looking to defend the health and safety of their employees in a changing climate
Skin concern(s): Rough & flaky skin, uneven skin tone and texture, pigmentation, dull skin, dark circles
The test reveals genetic predispositions in GLP-1 receptor sensitivity and inflammatory pathways that may influence side effect patterns